JP2009517343A - 組織損傷のための幹細胞因子療法 - Google Patents

組織損傷のための幹細胞因子療法 Download PDF

Info

Publication number
JP2009517343A
JP2009517343A JP2008540240A JP2008540240A JP2009517343A JP 2009517343 A JP2009517343 A JP 2009517343A JP 2008540240 A JP2008540240 A JP 2008540240A JP 2008540240 A JP2008540240 A JP 2008540240A JP 2009517343 A JP2009517343 A JP 2009517343A
Authority
JP
Japan
Prior art keywords
scf
nucleic acid
cells
injury
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008540240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517343A5 (https=
Inventor
ツェボ，クリスティーナ，エム．
Original Assignee
エンタープライズ パートナーズ ベンチャー キャピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンタープライズ パートナーズ ベンチャー キャピタル filed Critical エンタープライズ パートナーズ ベンチャー キャピタル
Publication of JP2009517343A publication Critical patent/JP2009517343A/ja
Publication of JP2009517343A5 publication Critical patent/JP2009517343A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008540240A 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法 Pending JP2009517343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73705805P 2005-11-14 2005-11-14
PCT/US2006/043937 WO2007059010A2 (en) 2005-11-14 2006-11-13 Stem cell factor therapy for tissue injury

Publications (2)

Publication Number Publication Date
JP2009517343A true JP2009517343A (ja) 2009-04-30
JP2009517343A5 JP2009517343A5 (https=) 2010-01-07

Family

ID=38049189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540240A Pending JP2009517343A (ja) 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法

Country Status (7)

Country Link
US (1) US8404653B2 (https=)
EP (1) EP1948246B1 (https=)
JP (1) JP2009517343A (https=)
CN (1) CN101563097A (https=)
AU (1) AU2006315601A1 (https=)
CA (1) CA2629775A1 (https=)
WO (1) WO2007059010A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009073822A (ja) * 2007-08-24 2009-04-09 Okayama Univ Ｅｃｐを有効成分とする左室リモデリングの予防及び治療剤。

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
GB201400562D0 (en) 2014-01-14 2014-03-05 Orla Protein Technologies Ltd Protein coated polymeric substrate
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2019200240A1 (en) * 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-scf) lipid nanocarriers and methods of use thereof
JP2022526187A (ja) * 2019-04-12 2022-05-23 エモリー ユニバーシティー 造血細胞の細胞傷害性を促進するための組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003069310A2 (en) * 2002-02-14 2003-08-21 Buck Institute Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
WO2005053729A1 (en) * 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
US6326198B1 (en) * 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5827216A (en) * 1995-06-07 1998-10-27 Cormedics Corp. Method and apparatus for accessing the pericardial space
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2213906A1 (en) 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6258119B1 (en) 1996-11-07 2001-07-10 Myocardial Stents, Inc. Implant device for trans myocardial revascularization
US5931810A (en) * 1996-12-05 1999-08-03 Comedicus Incorporated Method for accessing the pericardial space
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
DE69837491T2 (de) * 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. Menschliche mesenchymale stammzellen aus peripherem blut
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6251418B1 (en) 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US7078387B1 (en) * 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
WO2002030443A2 (en) 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
EP1379197A4 (en) * 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US20070238675A1 (en) * 2003-08-11 2007-10-11 Phillips M I Stem Cell Beacon
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003069310A2 (en) * 2002-02-14 2003-08-21 Buck Institute Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
WO2005053729A1 (en) * 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009073822A (ja) * 2007-08-24 2009-04-09 Okayama Univ Ｅｃｐを有効成分とする左室リモデリングの予防及び治療剤。

Also Published As

Publication number Publication date
US20090304636A1 (en) 2009-12-10
AU2006315601A1 (en) 2007-05-24
CN101563097A (zh) 2009-10-21
US8404653B2 (en) 2013-03-26
EP1948246A2 (en) 2008-07-30
CA2629775A1 (en) 2007-05-24
WO2007059010A2 (en) 2007-05-24
EP1948246A4 (en) 2010-04-28
WO2007059010A3 (en) 2009-04-30
EP1948246B1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
Johnson et al. Approaches to therapeutic angiogenesis for ischemic heart disease
Mitsos et al. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials
AU2008232739B2 (en) Method of treating ischemic disorders
US20040161412A1 (en) Cell-based VEGF delivery
JP2010174017A (ja) Ｆｇｆの脈管形成的に有効な単位用量および投与方法
Thiagarajan et al. Angiogenic growth factors in myocardial infarction: a critical appraisal
Bobek et al. Gene therapy of the ischemic lower limb—Therapeutic angiogenesis
JP2012100670A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
JP2005336202A (ja) マクロファージ炎症蛋白変種
US8404653B2 (en) Membrane bound stem cell factor therapy for ischemic heart
AU2014362198A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
Haider et al. Angiomyogenesis for myocardial repair
AU2003232152A1 (en) Intramyocardial injection of autologous bone marrow
US20190307688A1 (en) Novel stem cell carrier and method for preparing the same
US20050192242A1 (en) Therapeutic fusion protein transgenes
EP2964330A1 (en) Compositions and methods for cardiac tissue repair
JP5467742B2 (ja) Ｅｃｐを有効成分とする左室リモデリングの予防及び治療剤。
WO2011154308A1 (en) New compositions and cell therapy methods for the treatment of cirrhosis
Sprengers et al. Growth factor and cell therapy in patients with critical limb ischemia
RU2628706C2 (ru) Способ стимуляции ангиогенеза в ишеминизированных тканях и комбинированное лекарственное средство для осуществления способа
Bahrami Therapeutic Efficacy of Cellular Transplantation for Cardiac Repair
Wnek et al. Gene-Activated Matrix/Neil Davies
Beohar et al. Cytokine treatment for cardioprotection and cardiac regeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120807